Dr. Weiner on the T-DM1 Mechanism of Action

Video

In Partnership With:

Dr. Louis Weiner, from Lombardi Comprehensive Cancer Center, on the T-DM1 mechanism of action in HER2-positive breast cancer.

Louis M. Weiner, MD, Director, Lombardi Comprehensive Cancer Center, Associate Vice President, Georgetown University Medical Center, discusses the mechanism of action for the antibody drug conjugate trastuzumab emtansine (T-DM1), which combines the anti-HER2 antibody trastuzumab (Herceptin) with the cytotoxin mertansine, also called DM1.

Weiner explains that T-DM1 works in several different ways. First, trastuzumab selectively binds to HER2 receptors and is internalized by the cancer cell. In addition to the antitumor activity initiated by trastuzumab, once internalized by the cancer cell, DM1 is selectively liberated causing apoptosis.

T-DM1 demonstrated an impressive survival benefit in the phase III EMILIA trial, which compared T-DM1 to capecitabine plus lapatinib for women with HER2-positive locally advanced or metastatic breast cancer.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD